Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Johnson and Johnson
Mallinckrodt
Dow
McKinsey

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,507,460

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,507,460
Title:Substituted 3\',5\'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
Inventor(s): Surleraux; Dominique (Wauthier-Braine, BE), Dousson; Cyril B. (Canet, FR), Parsy; Christophe Claude (Jacou, FR)
Assignee: Idenix Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:13/650,739
Patent Claims:1. A compound of Formula I: ##STR00009## or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein R.sup.1 is lower alkyl or hydrogen, and R.sup.2 is lower alkyl.

2. The compound of claim 1 wherein R.sup.1 is hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or t-butyl.

3. The compound of claim 1 wherein R.sup.2 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, cyclopentyl, cyclobutyl, cyclopropyl or t-butyl.

4. The compound of claim 1 according to formula Ia or Ib: ##STR00010## or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof.

5. The compound of claim 1 according to formula II: ##STR00011## or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof.

6. The compound of claim 1 according to formula IIa or IIb: ##STR00012## or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof.

7. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient, carrier or diluent.

8. The pharmaceutical composition of claim 7, wherein the composition is an oral formulation.

9. A pharmaceutical composition comprising the compound of claim 5 and a pharmaceutically acceptable excipient, carrier or diluent.

10. The pharmaceutical composition of claim 9, wherein the composition is an oral formulation.

11. A method for the treatment of a host infected with a hepatitis C virus, comprising the administration of an effective treatment amount of a compound of claim 1.

12. The method of claim 11, wherein the host is a human.

13. The method of claim 11, wherein said administration directs a substantial amount of said compound or pharmaceutically acceptable salt or stereoisomer thereof to the liver of said host.

14. The method of claim 11, wherein said compound is administered in combination or alternation with a second anti-viral agent optionally selected from the group consisting of an interferon, a ribavirin, an interleukin, a NS3 protease inhibitor, a cysteine protease inhibitor, a phenanthrenequinone, a thiazolidine derivative, a thiazolidine, a benzanilide, a helicase inhibitor, a polymerase inhibitor, a nucleotide analogue, a gliotoxin, a cerulenin, an antisense phosphorothioate oligodeoxynucleotide, an inhibitor of IRES-dependent translation, and a ribozyme.

15. The method of claim 14, wherein the second agent is selected from the group consisting of telaprevir, bocepravir, pegylated interferon alpha 2a, interferon alphacon-1, natural interferon, albuferon, interferon beta-1a, omega interferon, interferon alpha, interferon gamma, interferon tau, interferon delta and interferon .gamma.-1b.

16. A method for the treatment of a host infected with a hepatitis C virus, comprising the administration of an effective treatment amount of a compound of claim 5.

17. The method of claim 16, wherein the host is a human.

18. The method of claim 16, wherein said administration directs a substantial amount of said compound or pharmaceutically acceptable salt or stereoisomer thereof to the liver of said host.

19. The method of claim 16, wherein said compound is administered in combination or alternation with a second anti-viral agent optionally selected from the group consisting of an interferon, a ribavirin, an interleukin, a NS3 protease inhibitor, a cysteine protease inhibitor, a phenanthrenequinone, a thiazolidine derivative, a thiazolidine, a benzanilide, a helicase inhibitor, a polymerase inhibitor, a nucleotide analogue, a gliotoxin, a cerulenin, an antisense phosphorothioate oligodeoxynucleotide, an inhibitor of IRES-dependent translation, and a ribozyme.

20. The method of claim 19, wherein the second agent is selected from the group consisting of telaprevir, bocepravir, pegylated interferon alpha 2a, interferon alphacon-1, natural interferon, albuferon, interferon beta-1a, omega interferon, interferon alpha, interferon gamma, interferon tau, interferon delta and interferon .gamma.-1b.

Details for Patent 8,507,460

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17   Start Trial Idenix Pharmaceuticals, Inc. (Cambridge, MA) 2036-04-30 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 001 2002-03-07   Start Trial Idenix Pharmaceuticals, Inc. (Cambridge, MA) 2036-04-30 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 002 2002-03-07   Start Trial Idenix Pharmaceuticals, Inc. (Cambridge, MA) 2036-04-30 RX search
Vidara Therapeutics Research Ltd ACTIMMUNE interferon gamma-1b VIAL; SINGLE-USE 103836 001 1999-02-25   Start Trial Idenix Pharmaceuticals, Inc. (Cambridge, MA) 2036-04-30 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Colorcon
Harvard Business School
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.